OBJECTIVE
To study the impact of polysaccharide-iron (III) complex application for intravenous administration in addition to the background therapy of chronic heart failure on cytokine aggression, NT-proBNP and erythropoietin levels, as well as on the morphofunctional parameters of the heart in patients with anemia and iron deficiency.
MATERIALS AND METHODS
During the study, 126 patients with chronic heart failure (CHF) of ischemic etiology were examined, of whom 92 patients (37 men and 55 women) had anemia (study group) and 34 patients (13 men and 21 women) had no anemia (control group). Among 126 patients, 89 (70.6%) were diagnosed with functional class I—II of CHF and 37 (29.4%) — with FC III—IV. Patients of the study group were divided into two groups depending on the treatment strategy. Group І consisted of 49 patients (26 men and 23 women; mean age — 61.1±1.4 years), who received only the background therapy of CHF according to clinical guidelines. Group ІІ included 43 patients who received combined therapy with disease-modifying agents for CHF and polysaccharide-iron (III) complex (Venofer) at a dose of 200 mg intravenously twice a week for 5 weeks.
RESULTS
It has been shown that the addition of polysaccharide-iron (III) complex (Venofer) to the background therapy of CHF for intravenous administration causes an increase in hemoglobin level by 5.2% (p<0.05), serum ferritin by 2 times (p<0.01) and transferrin saturation of more than 20%, as well as a reduction in NT-proBNP level in patients with CHF with anemia and iron deficiency, normo- and hypererythropoietinemia. An improvement in the left ventricular systolic and diastolic function indicators has been shown in the combined therapy as well. Distance during the 6-minute walk test increased (p<0.05) in patients of group II: on average by 24.5% in subjects with FC I—II and by 21.5% — in subjects with FC III—IV. An increase in the glomerular filtration rate was 12.4% (p<0.05) in patients of group II with FC I—II of CHF and 22.8% (p<0.001) — in patients with FC III—IV of CHF.
CONCLUSION
Intravenous administration polysaccharide-iron (III) complex in patients with chronic heart failure with anemia and iron deficiency increases hemoglobin and ferritin levels, reduces NT-proBNP level, does not affect cytokine aggression and erythropoietin level.
